sildosin
PreclinicalSmall molecule
sildosin is one of 2 small molecule programs targeting Dilation. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1 competitor in Dilation
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Premature Ejaculation1 trial
On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation
Completed·—·Phase 2/3·NCT07081659·95 enrolled
Dilation1 trial
Pre-Op Sildosine and Ureteral Dilation During F-URS
Completed·—·N/A·NCT05798572·140 enrolled
Outcome1 trial
Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH
Unknown status·—·Phase 2·NCT04590534·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sildosin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBenha University